Evidence base
Polyoxidonium® studies are conducted in accordance with high international standards

The International Multicenter Clinical Study (IMCS) of the safety and efficacy of Polyoxidonium® for the treatment of COVID-19 is carried out in accordance with the WHO international protocol, which is a high standard of evidence-based medicine.
Polyoxidonium® is registered in Europe (Slovakia) and complies with all EU regulatory requirements. Besides, Polyoxidonium® is also included in the European clinical practice guidelines (Slovakia) for the treatment of coronavirus infection.
Research results
Double-blind, randomized, placebo-controlled clinical studies of efficacy and safety have shown that Polyoxidonium® as part of ARI therapy can2,3,4:

For the 6-month observation period, no negative changes in the patients' condition were observed, which is indicative of a high safety profile of Polyoxidonium®.


A meta-analysis of efficacy and safety clinical studies has shown that in the treatment of infectious and inflammatory diseases of the respiratory tract, Polyoxidonium® can5:
PASS
In 2017 the PASS (Post-Authorisation Safety Study) — a multicenter, prospective, open-label, non-interventional post-authorisation safety study — was completed in Europe (Slovakia)6.
The safety profile was confirmed in all categories of patients.
Polyoxidonium® is included into guidelines and supported by leading scientific organizations:
- Guidelines of the National Medical Association of Otorhinolaryngologists "Acute sinusitis" (approved by N.A. Daikhes and Yu.K. Yanov), 2018.
- Guidelines of the National Medical Association of Otorhinolaryngologists "Acute rhinitis" (approved by N.A. Daikhes and Yu.K. Yanov), 2018.
- Guidelines for Vaccination and Immunotherapy for ENT pathology (edited by M.P. Kostinov), 2019.
- Otorhinolaryngology, Standards of Medical Care, GEOTAR, 2019.
Learn more
WHY POLYOXIDONIUM®?


Why Polyoxidonium®?

- Patient information leaflet for Polyoxidonium®.
- Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
- Garaschenko, T.I., Karneeva, O.V., Tarasova, G.D., et al. (2020). Influence of local application of Polyoxidonium on symptoms and course of acute respiratory viral infection in children: results of multicenter double-blind placebo-controlled study. Consilium Medicum, 22(3), 80–86.
- Kharlamova, F.S., Uchaikin, V.F., et al. (2013). Experience of Polyoxidonium immunomodulator for the treatment of acute respiratory infections in children. Effective Pharmacotherapy. Epidemiology and Infections, 1(11), 12–20.
- Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
- Pruzinec, P., Chirun, N., Sveikata, A. (2018). The safety profile of Polyoxidonium in daily practice: results from postmarketing safety study in Slovakia. Immunotherapy, 10(2), 1–7.
- Letter of the Russian Association of Allergologists and Clinical Immunologists concerning Polyoxidonium® application.